Statute Details
- Title: Medicines (Veterinary Medicinal Products) (Import and Product Licences) Regulations
- Act Code: MA1975-RG1
- Type: Subsidiary Legislation (sl)
- Authorising Act: Medicines Act (Chapter 176), Section 74
- Regulation Citation: Rg 1
- Government Gazette / Citation: G.N. No. S 145/1977
- Revised Edition: 2000 RevEd (31 January 2000)
- Status: Current version as at 27 Mar 2026 (per provided extract)
- Key Provisions (from extract): Regulations 3–14 (notably: validity periods, application requirements, post-licence duties, records, substandard products, fees, and penalty)
What Is This Legislation About?
The Medicines (Veterinary Medicinal Products) (Import and Product Licences) Regulations (“the Regulations”) form part of Singapore’s regulatory framework for veterinary medicines. In plain terms, they control who may import veterinary medicinal products and who may hold licences to market or supply them, by requiring licensing, evidence of safety/quality/efficacy, and ongoing reporting and record-keeping.
The Regulations are designed to ensure that veterinary medicinal products entering or circulating in Singapore meet specified standards and that regulators can trace products and respond quickly if safety concerns arise. They also create administrative mechanisms for licensing authorities to request information, require updates, and direct withholding of products suspected to be substandard.
Although the extract focuses on product and import licences, the Regulations operate as a compliance “bridge” between scientific/technical submissions (e.g., studies, hazards, precautions) and practical regulatory controls (e.g., records, notifications, and enforcement). For practitioners, the key is that licensing is not a one-off event: licence holders must actively manage changes, report adverse effects, and notify withdrawals.
What Are the Key Provisions?
1) Licence validity periods (Regulations 3 and 4)
Regulation 3 sets the duration of product licences. A product licence (other than a provisional product licence) is granted for 5 years, or for a shorter period if the licensing authority determines. A provisional product licence is granted for 2 years, again subject to the licensing authority’s discretion to shorten the period. This structure suggests a regulatory pathway where provisional licences may be used when full data or confirmation is still being developed, while still allowing controlled market access.
Regulation 4 governs import licences. Each import licence is valid only for one consignment of veterinary medicinal products for which the application was made. The import licence is valid for one month from the date of issue. This consignment-based approach limits the risk of “over-importing” under a single approval and ensures that import controls align with specific shipments.
2) Application requirements and how licences are obtained (Regulations 5 and 6)
Regulation 5 requires that applications for a product licence or provisional product licence be made to the licensing authority in the required form and manner, accompanied by required information, documents, samples, and other material. Critically, Regulation 5(2) requires a separate application for each veterinary medicinal product. However, Regulation 5(3) allows a single application covering 2 or more products if they share the same pharmaceutical form and consist of either (a) a single active constituent in different strengths, or (b) mixtures of active constituents in different strengths but in the same proportion. This is a practical “grouping” rule that reduces administrative burden while maintaining scientific comparability.
Regulation 6 specifies the kinds of particulars that must be submitted. These include: (a) chemical, pharmaceutical, experimental and biological studies; (b) animal tests and studies; (c) possible hazards to man, livestock and wildlife; and (d) precautions or contra-indications. For counsel advising applicants, this provision is central: it frames the evidentiary content expected for licensing and signals that safety considerations extend beyond animals to humans and wildlife.
3) Ongoing duties after licensing: changes, new information, adverse effects, and withdrawal (Regulations 7–10)
Once a licence is granted, the holder must manage regulatory updates. Regulation 7 requires the holder to forthwith inform the licensing authority of any material change made or proposed in the application particulars. The regulation lists key areas: (a) product specifications; (b) specifications of constituents; (c) composition; and (d) methods/procedures ensuring compliance with specifications. The “forthwith” standard is strict and is likely to be interpreted as prompt notification without undue delay.
Regulation 8 imposes a similar “forthwith” duty where the holder receives information that casts doubt on the continued validity of data submitted for assessing safety, quality, or efficacy. This is an important compliance trigger: even if the product has not changed, new evidence undermining the original data must be reported.
Regulation 9 requires reporting of adverse effects on human beings or animals (or both) associated with the veterinary medicinal product or its constituents. The licensing authority may also require the holder to furnish copies of reports. Regulation 10 then addresses commercial lifecycle decisions: if the holder decides to withdraw from sale, supply or exportation, it must notify the licensing authority forthwith and state the reason for the decision. Together, these provisions create a continuous safety and market integrity obligation.
4) Records, substandard products, fees, and penalties (Regulations 11–14)
Regulation 11 is a record-keeping and traceability requirement. An importer must keep records of imports and distribution of veterinary medicinal products readily available for inspection by the licensing authority. When directed, the importer must submit such records. The records must not be destroyed for 5 years from the date of importation, and must facilitate withholding from sale, supply or exportation. This is a practical compliance design: if regulators need to act quickly, they should be able to identify where products went.
Regulation 12 addresses quality failures. Where a veterinary medicinal product is suspected or found not to conform regarding strength, quality or purity with the product specification or the Medicines Act/regulations, the licensing authority may direct the importer (or any person in possession) to withhold the product from sale, supply or exportation for a specified period. This is a powerful regulatory tool, enabling containment while investigations or remediation occur.
Regulation 13 sets fees: $3 per consignment for an import licence; $50 per product for a product licence; and $25 per product for a provisional product licence. These fees are relatively modest, but the compliance burden is driven by evidentiary and reporting obligations rather than cost.
Finally, Regulation 14 provides enforcement. Any person who contravenes or fails to comply with Regulations 7, 8, 9, 10 or 11, or fails to comply with a direction under Regulation 12, commits an offence. On conviction, the person is liable to a fine not exceeding $2,000. For practitioners, this penalty provision is significant because it ties criminal liability to specific post-licence duties and to compliance with regulatory directions.
How Is This Legislation Structured?
The Regulations are structured as a sequence of licensing and compliance rules:
Regulations 1–2 provide citation and definitions (notably defining “importer”). Regulations 3–4 set validity periods for product and import licences. Regulations 5–6 govern applications and the submission of scientific and safety-related particulars. Regulations 7–10 impose ongoing notification duties for material changes, doubts about submitted data, adverse effects, and withdrawal decisions. Regulation 11 requires record-keeping by importers. Regulation 12 empowers the licensing authority to direct withholding of suspected substandard products. Regulation 13 sets licence fees. Regulation 14 establishes penalties for contraventions and failures to comply with directions.
Who Does This Legislation Apply To?
The Regulations apply to persons involved in the importation and licensing of veterinary medicinal products in Singapore. In particular, the licensing and product-holder duties in Regulations 3–10 apply to holders of product licences or provisional product licences. The importer-specific duties in Regulation 11 apply to an importer (as defined in Regulation 2).
Regulation 12 extends practical reach beyond the importer: where a product is suspected or found substandard, the licensing authority may direct the importer or any person in possession to withhold the product. This means distributors, warehouse holders, or other intermediaries who physically possess product may need to ensure they can comply with regulatory directions and support traceability.
Why Is This Legislation Important?
For legal practitioners, the Regulations are important because they convert scientific licensing into enforceable operational duties. The licensing authority is not limited to reviewing initial submissions; it can require updates when data becomes questionable, when adverse effects are reported, and when material changes occur. This creates a compliance regime that is both evidence-based and responsive.
The consignment-based import licence validity (one consignment, one month) and the importer record-keeping obligations (five-year retention and traceability) are particularly relevant for enforcement and disputes. If a product is later found to be substandard or if adverse effects are reported, the ability to trace distribution and demonstrate compliance becomes central.
Finally, the penalty provision, while capped at a fine not exceeding $2,000, is tied to specific regulatory breaches and to non-compliance with withholding directions. In practice, even where penalties are modest, contraventions can trigger regulatory escalation, reputational harm, and potential downstream consequences under the broader Medicines Act framework. Advisers should therefore treat these Regulations as a core compliance document for veterinary medicinal product supply chains.
Related Legislation
- Medicines Act (Chapter 176) (authorising provision: Section 74)
Source Documents
This article provides an overview of the Medicines (Veterinary Medicinal Products) (Import and Product Licences) Regulations for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.